A twice-yearly injection called lenacapavir has emerged as one of the most promising tools in HIV prevention, offering a solution to the adherence crisis that has long undermined daily pill regimens. Yet as with so many medical breakthroughs, the distance between scientific possibility and human reality is measured not in laboratories but in supply chains, pricing negotiations, and the quiet invisibility of those most at risk. The drug's capacity to reshape the epidemic depends less on its molecular elegance than on whether the world can find the will — and the reach — to deliver it to those w
Lenacapavir's HIV Promise Hinges on Access and Reaching Those Most at Risk
HIV continues spreading among vulnerable populations including adolescent girls and young women in Africa, younger gay men, and marginalized communities in Eastern Europe and Central Asia.
Those at highest risk don't see themselves at risk. That's why they're at risk.
Mark
Why does a twice-yearly injection matter so much more than a daily pill, if both deliver the same protection?
Mimi
Because asking healthy people to take medication every day is asking them to build a habit around something they can't feel happening. Half quit within three months. By year's end, almost nobody's left. An injection every six months? You show up twice. That's it.
Mark
And the drug itself—why is targeting the capsid different from what older PrEP drugs do?
Mimi
Older drugs block the enzymes the virus uses to copy itself. Lenacapavir goes after the shell that holds the virus together. It's like the difference between cutting off a supply line versus dismantling the container. The capsid is essential to everything HIV does, so it's a perfect target.
Mark
The numbers sound promising—preventing twelve to eighteen percent of infections. Why isn't that enough?
Mimi
Because it only works if the drug reaches the people who need it most. And right now, some countries are excluded entirely. Brazil, Mexico, Peru, Argentina—they tested the drug, but they're not in the rollout agreements.
Mark
What's the real barrier, then? Money?
Mimi
Money is part of it. But the deeper barrier is that the people at highest risk often don't see themselves that way. A young woman whose partner controls whether a condom gets used—she may not think of herself as high-risk. That's the paradox. Lenacapavir solved the adherence problem. It can't solve the problem of invisibility.
Mark
So the drug is almost secondary to the question of who gets it?
Mimi
Exactly. The drug works superbly. The question is whether it ever reaches the people it was designed to protect.
Le Pouls
- Half of all PrEP users abandon their daily pills within three months, leaving millions of people biologically unprotected despite having access to a drug that works.
- Lenacapavir — just two injections per year — dissolves the adherence burden entirely, and early modeling suggests it could prevent up to 18% of new infections over a decade if deployed strategically.
- Gilead has struck agreements to supply the drug at no profit to two million people and allow generic production in 120 countries, but Brazil, Mexico, Peru, and Argentina were excluded despite participating in clinical trials.
- Doctors Without Borders is pressing for direct sales at roughly forty dollars per injection, warning that even well-intentioned rollout agreements leave critical gaps in coverage.
- The hardest obstacle is not price or logistics but invisibility — adolescent girls in sub-Saharan Africa, younger gay men, and marginalized communities in Eastern Europe often do not perceive themselves as at risk, and no injection can reach someone who never comes forward.
A twice-yearly injection called lenacapavir has emerged as one of the most promising tools in HIV prevention, offering a solution to the adherence crisis that has long undermined daily pill regimens. Yet as with so many medical breakthroughs, the distance between scientific possibility and human reality is measured not in laboratories but in supply chains, pricing negotiations, and the quiet invisibility of those most at risk. The drug's capacity to reshape the epidemic depends less on its molecular elegance than on whether the world can find the will — and the reach — to deliver it to those who need it most.
A young woman in South Africa may not know her partner's HIV status, may have little power to negotiate condom use, and may struggle to take a pill every single day while healthy. That last difficulty — the daily discipline of prevention — has quietly undermined HIV protection for years. Roughly half of people who begin PrEP stop within three months. The medication works, but only for those who keep taking it.
Lenacapavir offers a different proposition: two injections per year. The drug targets HIV's capsid shell — the cone-shaped casing around the virus's genetic material — through a mechanism unlike any older PrEP medication. It lingers in the body at low but protective concentrations, described by one biochemist as a slow-dissolving depot. For those who receive it consistently, it is among the most potent anti-HIV molecules known.
The rollout has begun. South Africa started distributing lenacapavir to high-risk populations in mid-2026, backed by a Gilead agreement with the Global Fund to supply the drug at no profit to up to two million people. Generic production rights have been extended to 120 resource-limited countries. Epidemiological modeling suggests that reaching even two to four percent of adults — with deliberate focus on the most vulnerable — could avert twelve to eighteen percent of new infections over a decade.
Yet the picture is uneven. Several Latin American countries that participated in clinical trials were excluded from supply agreements. Doctors Without Borders is pushing for direct access at around forty dollars per injection. And even where the drug is available, the deepest challenge remains unchanged: people at highest risk often do not see themselves that way. Adolescent girls, younger gay men, communities in Eastern Europe and Central Asia — they may never seek out a drug they do not believe they need.
Lenacapavir solves the adherence problem. It cannot solve the problem of invisibility. Its ultimate impact on the epidemic will be determined by three things: whether prices stay affordable, whether distribution reaches beyond the easiest populations, and whether public health systems find ways to see — and serve — those who remain hardest to reach.
A young woman in South Africa faces a choice that millions confront silently. She may not know whether her partner carries HIV. She may struggle to insist on condom use. She may have little say in whether he sleeps with others. For her, a daily pill—Pre-Exposure Prophylaxis, or PrEP—offers protection, but only if she remembers to take it every single day.
That daily requirement has become the central problem in HIV prevention. Salim Abdool Karim, who directs the Centre for the AIDS Programme of Research in South Africa, describes it plainly: "You're asking people who are healthy, who don't have any illness, to take a tablet every day. That's a high bar." His own research, along with studies from elsewhere, tells a sobering story. About half of people who start PrEP abandon it within three months. By the end of a year, only a handful remain. The medication works brilliantly—but only for those who actually take it.
Enter lenacapavir. One injection, twice yearly. For people who receive it consistently, the results are striking. Wesley Sundquist, a biochemist at the University of Utah who specializes in HIV's structure, calls it "the most potent molecule we know of against HIV." The drug works through an entirely different mechanism than older PrEP medications. Rather than blocking the enzymes the virus uses to replicate, lenacapavir targets the capsid—the cone-shaped shell that encloses the virus's genetic material. This shell is essential to how HIV reproduces, making it an elegant target. The drug persists in the body at low but protective concentrations, Sundquist explains, like "a little depot that slowly dissolves."
The promise is real. In June 2026, South Africa began rolling out lenacapavir to people at high risk, backed by an agreement Gilead struck with the Global Fund in July 2025. The company committed to supplying the drug at no profit to up to two million people over three years. Earlier, in October 2024, Gilead had already agreed to allow generic versions to be produced in 120 resource-limited countries where HIV infection rates remain elevated. The mathematics of prevention look encouraging too. Monisha Sharma, an epidemiologist at the University of Washington, modeled the drug's impact in South Africa, Zimbabwe, and western Kenya. If lenacapavir reached just two to four percent of the adult population—with deliberate focus on those at greatest risk—it could avert twelve to eighteen percent of new infections over a decade.
But the picture fractures when you examine who actually has access. Melissa Scharwey of Doctors Without Borders points out that several Latin American countries—Brazil, Mexico, Peru, Argentina—were excluded from recent lenacapavir agreements despite having participated in the drug's clinical trials. Even within countries where the drug is available, vulnerable populations may be overlooked. Scharwey calls for Gilead to increase supply and sell directly to her organization at around forty dollars per injection, a price she considers affordable for widespread use.
The deeper challenge, though, is not primarily about money or logistics. It is about finding people who do not yet see themselves as at risk. Abdool Karim articulates this with clarity born from decades of work: "The problem is that those at highest risk need to come forward to take the medication. And often those at the highest risk don't see themselves at risk. That's why they're at risk." Lenacapavir solves the adherence problem—the daily burden that defeats so many. It cannot solve the harder problem: identifying and reaching adolescent girls and young women in parts of Africa, younger gay men in Western countries, and vulnerable communities in Eastern Europe and Central Asia, before they become infected.
Sharma's conclusion is measured but clear. Lenacapavir could substantially accelerate progress toward lower infection rates, but it is unlikely to eliminate HIV transmission on its own. That impact depends entirely on three conditions: affordable drug prices, efficient distribution channels, and targeted uptake among people with the highest risk. The first two are matters of will and resources. The third remains the hardest problem in public health—reaching people who are invisible to themselves.
Citations marquantes
You're asking people who are healthy, who don't have any illness, to take a tablet every day. That's a high bar.— Salim Abdool Karim, Centre for the AIDS Programme of Research in South Africa
It is the most potent molecule we know of against HIV, and it remains effective over long periods even at low concentrations.— Wesley Sundquist, University of Utah biochemist
Envie de l'histoire complète ?
Lire l'original sur Deutsche Welle ↗
Health & Medicine